Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes

被引:139
作者
Johnson, JA
Simpson, SH
Toth, EL
Majumdar, SR
机构
[1] Inst Hlth Econ, Edmonton, AB, Canada
[2] Univ Alberta, Dept Publ Hlth Sci, Edmonton, AB, Canada
[3] Univ Alberta, Dept Med, Div Endocrinol & Metab, Edmonton, AB, Canada
[4] Univ Alberta, Dept Med, Div Gen Internal Med, Edmonton, AB, Canada
关键词
diabetes mellitus; metformin; morbidity and mortality; propensity score;
D O I
10.1111/j.1464-5491.2005.01448.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim Metformin therapy reduces microvascular complications in Type 2 diabetes; questions remain, however, regarding its impact on macrovascular events. This study examined metformin use in relation to risk of cardiovascular-related hospitalization and mortality. Methods We conducted a retrospective cohort analysis, using Saskatchewan Health administrative databases to identify new users of oral antidiabetic drugs. Subject groups were defined by medication use during 1991-1999: sulphonylurea monotherapy, metformin monotherapy, or combination therapy. Deaths and non-fatal hospitalizations recorded during the study period were identified as cardiovascular-related from ICD-9 codes. The main outcome was a composite of first non-fatal hospitalization or death. Standard multivariate techniques, including propensity scores, were used to adjust for potential confounding. Multivariate Cox proportional hazard models were used to examine the relationship between metformin use and the composite endpoint. Results Metformin monotherapy was associated with a lower risk of the composite endpoint (adjusted hazard ratio 0.81; 95% confidence interval 0.68, 0.97) compared with sulphonylurea monotherapy. Combination therapy with meformin and a sulphonylurea was associated with lower mortality, but had similar hospitalization rates, to sulphonylurea monotherapy. Conclusions Metformin monotherapy was associated with a lower risk of cardiovascular-related morbidity and mortality, and combination metformin and sulphonylurea therapy was associated with a reduced risk of fatal cardiovascular events, when compared with sulphonylurea monotherapy.
引用
收藏
页码:497 / 502
页数:6
相关论文
共 30 条
[1]   Diabetes-related morbidity and mortality in a national sample of US elders [J].
Bertoni, AG ;
Anderson, GF ;
Krop, JS ;
Brancati, FL .
DIABETES CARE, 2002, 25 (03) :471-475
[2]   Randomized, controlled trials, observational studies, and the hierarchy of research designs. [J].
Concato, J ;
Shah, N ;
Horwitz, RI .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1887-1892
[3]   The importance of validating the diagnosis of coronary heart disease when measuring secondary prevention: a cross-sectional study in general practice [J].
Connolly, P ;
Cupples, ME ;
Cuene-Grandidier, H ;
Johnston, D ;
Passmore, P .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2002, 11 (04) :311-317
[4]  
COX DR, 1972, J R STAT SOC B, V34, P187
[5]  
D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO
[6]  
2-B
[7]   EFFICACY OF METFORMIN IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J].
DEFRONZO, RA ;
GOODMAN, AM ;
ABELOVE, W ;
REID, E ;
PITA, J ;
CALLAHAN, M ;
JOHNSON, D ;
PELAYO, E ;
PUGH, J ;
SHANK, M ;
GARZA, P ;
HAAG, B ;
KORFF, J ;
ANGELO, A ;
IZENSTEIN, B ;
VANDERLEEDEN, M ;
CATHCART, H ;
TIERNEY, M ;
BIGGS, D ;
KARAM, J ;
NOLTE, M ;
GAVIN, L ;
ELDER, MA ;
CORBOY, J ;
THWAITE, D ;
WONG, S ;
DAVIDSON, M ;
PETERS, A ;
DUNCAN, T ;
KERCHER, S ;
FISCHER, J ;
KIPNES, M ;
RADNICK, BJ ;
ROURA, M ;
ROQUE, J ;
MONTGOMERY, C ;
COLLUM, P ;
RUST, M ;
POHL, S ;
PFEIFER, M ;
ALLWEISS, P ;
LEICHTER, S ;
LEACH, P ;
GALLINA, D ;
MUSEY, V ;
BERKOWITZ, K ;
EASTMAN, R ;
TAYLOR, T ;
DELAPENA, MS ;
ZAWADSKI, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (09) :541-549
[8]   Hospitalizations for people with type 1 and type 2 diabetes compared with the nondiabetic population of Tayside, Scotland - A retrospective cohort study of resource use [J].
Donnan, PT ;
Leese, GP ;
Morris, AD .
DIABETES CARE, 2000, 23 (12) :1774-1779
[9]  
Downey W, 2000, PHARMACOEPIDEMIOLOGY, V3rd, P325
[10]   METFORMIN - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J].
DUNN, CJ ;
PETERS, DH .
DRUGS, 1995, 49 (05) :721-749